{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:29:06Z","timestamp":1748968146769,"version":"3.41.0"},"reference-count":0,"publisher":"International Institute of Anticancer Research","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDP"],"published-print":{"date-parts":[[2024,11,2]]},"abstract":"<jats:p>Background\/Aim: The therapeutic efficacy of the paclitaxel (PTX) + cetuximab (Cmab) combination regimen was investigated in patients with recurrence or metastasis after superselective intraarterial chemoradiotherapy (SSIACRT) for oral cancer, and the safety was retrospectively examined. Patients and Methods: All enrolled patients with advanced oral cancer or who had refused surgery over 10 years from December 2012 to December 2022 underwent SSIACRT for 6 to 9 weeks [cisplatin (CDDP): total 160-630 mg\/m2 and radiotherapy: total 50-70 Gy]. Nine cases (tongue cancer, maxillary gingival cancer, and mandibular gingival cancer; three cases each) were subjected to PTX + Cmab therapy. Recurrence or metastases were observed within six months after the onset of treatment, complicating the conduct of salvage surgery. Cmab (first dose: 400 mg\/m2 and second and following doses: 250 mg\/m2) and PTX (80 mg\/m2) were administered weekly. Results: The overall response rate was 44.4% (four of nine cases), and the disease control rate was 88.9% (eight of nine cases), whereas the median progression-free survival was seven months, and the overall survival was 11 months. Grade 3-4 adverse events were neutropenia in 33.3% of the cases, leukopenia in 55.6%, anemia in 22.2%, and acneiform skin rash in 22.2%. Based on the above, PTX + Cmab therapy for recurrent and metastatic cases after SSIACRT had comparable results to other second-line modalities and enabled to cope with the side effects of myelosuppression. Conclusion: PTX + Cmab therapy may be an effective treatment mode for recurrent or metastatic head and neck cancer resistant to CDDP after SSIACRT treatment.<\/jats:p>","DOI":"10.21873\/cdp.10394","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:16:53Z","timestamp":1730801813000},"page":"769-774","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Paclitaxel and Cetuximab in Recurrent\/Metastatic Oral Cancer Cases Following Superselective Intraarterial Chemoradiotherapy: A Retrospective Cohort Study"],"prefix":"10.21873","volume":"4","author":[{"given":"KANAME","family":"SAKUMA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOMOYUKI","family":"KII","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOKO","family":"MACHIDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YOSUKE","family":"KIKUCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASAKI","family":"YODA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHUJI","family":"TOYA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AKIRA","family":"TANAKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"9336","published-online":{"date-parts":[[2024,11,2]]},"container-title":["Cancer Diagnosis &amp; Prognosis"],"original-title":[],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:17:05Z","timestamp":1730801825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancerdiagnosisprognosis.org\/article\/440\/efficacy-of-paclitaxel-and-cetuximab-in-recurrentmetastatic-oral-cancer-cases-following-superselective-intraarterial-chemoradiotherapy-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":0,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,11,2]]},"published-print":{"date-parts":[[2024,11,2]]}},"URL":"https:\/\/doi.org\/10.21873\/cdp.10394","relation":{},"ISSN":["2732-7787"],"issn-type":[{"type":"print","value":"2732-7787"}],"subject":[],"published":{"date-parts":[[2024,11,2]]}}}